Kaftrio الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - kystinen fibroosi - muut hengitysteiden tuotteet - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Enhertu الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - rintojen kasvaimet - antineoplastiset aineet - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Lumykras الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

IsoFlo vet 100 w/w% inhalaatiohöyry, neste فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

isoflo vet 100 w/w% inhalaatiohöyry, neste

zoetis animal health aps - isoflurane - inhalaatiohöyry, neste - 100 w/w% - isofluraani

Petrem Vet 100 % inhalaatiohöyry, neste فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

petrem vet 100 % inhalaatiohöyry, neste

piramal critical care b.v. - sevoflurane - inhalaatiohöyry, neste - 100 % - sevofluraani

Nitrosid 5 mg tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

nitrosid 5 mg tabletti

orion corporation - isosorbide dinitrate - tabletti - 5 mg - isosorbididinitraatti

Nitrosid 10 mg tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

nitrosid 10 mg tabletti

orion corporation - isosorbide dinitrate - tabletti - 10 mg - isosorbididinitraatti

Nitrosid 20 mg tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

nitrosid 20 mg tabletti

orion corporation - isosorbide dinitrate - tabletti - 20 mg - isosorbididinitraatti

Nitrosid Retard 20 mg depotkapseli, kova فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

nitrosid retard 20 mg depotkapseli, kova

orion corporation - isosorbide dinitrate - depotkapseli, kova - 20 mg - isosorbididinitraatti

Sedator vet 1.0 mg/ml injektioneste, liuos فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

sedator vet 1.0 mg/ml injektioneste, liuos

eurovet animal health b.v. - medetomidine hydrochloride - injektioneste, liuos - 1.0 mg/ml - medetomidiini